220 related articles for article (PubMed ID: 17909803)
1. Temozolomide in combination with fotemustine in patients with metastatic melanoma.
Tas F; Camlica H; Topuz E
Cancer Chemother Pharmacol; 2008 Jul; 62(2):293-8. PubMed ID: 17909803
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
3. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
4. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
Rixe O; Borel C; Paraiso D; Benhammouda A; Petit T; Antoine E; Bizzari JP; Auclerc G; Soubrane C; Weil M
Melanoma Res; 1995 Dec; 5(6):419-24. PubMed ID: 8589616
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
[TBL] [Abstract][Full Text] [Related]
6. Fotemustine plus dacarbazine for malignant melanoma.
Avril MF; Bonneterre J; Cupissol D; Grob JJ; Kalis B; Fumoleau P; Kerbrat P; Israel L; Fargeot P; Lambert D
Eur J Cancer; 1992; 28A(11):1807-11. PubMed ID: 1389514
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial.
Tas F; Argon A; Camlica H; Topuz E
Melanoma Res; 2005 Dec; 15(6):543-8. PubMed ID: 16314741
[TBL] [Abstract][Full Text] [Related]
9. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
10. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
Célérier P; Dreno B; Bureau B; Litoux P
Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group.
Avril MF; Bonneterre J; Delaunay M; Grosshans E; Fumoleua P; Israel L; Bugat R; Namer M; Cupissol D; Kerbrat P
Cancer Chemother Pharmacol; 1990; 27(2):81-4. PubMed ID: 2249337
[TBL] [Abstract][Full Text] [Related]
12. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
Comella P; Daponte A; Casaretti R; Ionna F; Fiore F; Presutti F; Frasci G; Caponigro F; Gravina A; Parziale AP; Mozzillo N; Comella G
Eur J Cancer; 1997 Jul; 33(8):1326-9. PubMed ID: 9301463
[TBL] [Abstract][Full Text] [Related]
13. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
Khayat D; Avril MF; Gerard B; Bertrand P; Bizzari JP; Cour V
Melanoma Res; 1992 Sep; 2(3):147-51. PubMed ID: 1450667
[TBL] [Abstract][Full Text] [Related]
14. Fotemustine plus dacarbazine in advanced stage III malignant melanoma.
Binder M; Winkler A; Dorffner R; Glebowski E; Wolff K; Pehamberger H
Eur J Cancer; 1992; 28A(11):1814-6. PubMed ID: 1389516
[TBL] [Abstract][Full Text] [Related]
15. [Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
Cui CL; Chi ZH; Yuan XQ; Lian HY; Si L; Guo J
Ai Zheng; 2008 Aug; 27(8):845-50. PubMed ID: 18710619
[TBL] [Abstract][Full Text] [Related]
16. The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
Guida M; Tommasi S; Strippoli S; Natalicchio MI; De Summa S; Pinto R; Cramarossa A; Albano A; Pisconti S; Aieta M; Ridolfi R; Azzariti A; Guida G; Lorusso V; Colucci G
BMC Cancer; 2018 May; 18(1):552. PubMed ID: 29747595
[TBL] [Abstract][Full Text] [Related]
17. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
18. Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.
Terheyden P; Becker JC; Kämpgen E; Bröcker EB
Melanoma Res; 2000 Oct; 10(5):475-82. PubMed ID: 11095409
[TBL] [Abstract][Full Text] [Related]
19. High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.
Guida M; Cramarossa A; Fistola E; Porcelli M; Giudice G; Lubello K; Colucci G
J Transl Med; 2010 Nov; 8():115. PubMed ID: 21067582
[No Abstract] [Full Text] [Related]
20. Fotemustine for the treatment of melanoma.
Quéreux G; Dréno B
Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
